Sandoz, a Novartis company and the global leader in biosimilars, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel® (etanercept) – a tumor necrosis factor alpha (TNF-alpha) inhibitor.
top of page
Search
Recent Posts
See AllGeneral Motors has secured an Indian patent on a hybrid powertrain control system for vehicles. The patent rights are currently assigned...
Taking into consideration the Delhi High court’s order staying the abandonment orders passed by the Trademarks Office, the Registrar of...
The order of the Delhi High Court allows the Competition Commission of India (CCI) to attend to complaints on abuse of dominance of...
bottom of page
Comments